Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment
Open Access
- 28 May 2010
- journal article
- case report
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 8 (1) , 45
Abstract
Renal cell carcinoma (RCC) represents approximately 3% of all adult cancers and is more common in males. Systemic treatment for RCC has improved following the introduction of tyrosine kinase inhibitors, such as sunitinib. The molecular targets of sunitinib are receptor tyrosine kinases (RTKs). Moreover, sunitinib has an additional anti-angiogenic effect through its inhibition of the vascular endothelial growth factor receptor activation.Keywords
This publication has 6 references indexed in Scilit:
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Long-term response with sunitinib for metastatic renal cell carcinomaUrology, 2006
- Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction PathwaySeminars in Oncology, 2006
- Renal abscessThe Journal of Emergency Medicine, 2006
- RENAL AND PERIRENAL ABSCESSESInfectious Disease Clinics of North America, 1997